{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:10:51Z","timestamp":1759731051090},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gefapixant, a P2X3\u2010receptor antagonist, demonstrated objective and subjective efficacy in individuals with refractory or unexplained chronic cough. We report a population pharmacokinetic (PopPK) analysis that characterizes gefapixant pharmacokinetics (PKs), quantifies between\u2010 and within\u2010participant variability, and evaluates the impact of intrinsic and extrinsic factors on gefapixant exposure. The PopPK model was initially developed using PK data from six phase I studies. Stepwise covariate method was utilized to identify covariates impacting PK parameters; the model was re\u2010estimated and covariate effects were re\u2010assessed after integrating PK data from three phase II and III studies. Simulations were conducted to evaluate the magnitude of covariate effects on gefapixant exposure. Of 1677 participants included in this data set, 1618 had evaluable PK records. Age, body weight, and sex had statistically significant, but not clinically relevant, effects on exposure. Degree of renal impairment (RI) had statistically significant and clinically relevant effects on exposure; exposure was 17% to 89% higher in those with versus without RI. Simulation results indicated that gefapixant 45\u2009mg administered once daily to patients with severe RI has similar exposure to gefapixant 45\u2009mg administered twice daily to patients with normal renal function. There were no significant effects of proton pump inhibitors or food. Of evaluated intrinsic and extrinsic factors, only RI had a clinically relevant effect on gefapixant exposure. Patients with mild or moderate RI do not require dosage adjustments; however, for patients with severe RI who are not on dialysis, gefapixant 45\u2009mg once daily is recommended.<\/jats:p>","DOI":"10.1002\/psp4.12978","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T06:32:00Z","timestamp":1683354720000},"page":"1107-1118","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population pharmacokinetic analysis of the <scp>P2X3\u2010receptor<\/scp> antagonist gefapixant"],"prefix":"10.1002","volume":"12","author":[{"given":"Akshita","family":"Chawla","sequence":"first","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Largajolli","sequence":"additional","affiliation":[{"name":"Certara Strategic Consulting  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azher","family":"Hussain","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huub","family":"Kleijn","sequence":"additional","affiliation":[{"name":"Certara Strategic Consulting  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihem","family":"Ait\u2010Oudhia","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Anton","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hari","family":"Krishna Ananthula","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Nussbaum","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"La\u00a0Rosa","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdous","family":"Gheyas","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.10.016"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-015-9701-2"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.05.038"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00160-2021"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-9974-3-5"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.11.018"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14677"},{"key":"e_1_2_12_9_1","unstructured":"Kyorin Pharmaceutical Co. Ltd.MSD K.K. receives manufacturing and marketing approval of LYFNUA\u00ae Tablets world's first selective P2X3 receptor antagonist for the treatment of chronic cough.https:\/\/www.kyorin\u2010pharm.co.jp\/en\/news\/2022\/001603.shtml. Accessed March 28 2023"},{"key":"e_1_2_12_10_1","unstructured":"Lyfnua\u00ae Filmtabletten (Gefapixantum).Swissmedic.https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/new\u2010medicines\/lyfnua\u2010filmtabletten\u2010gefapixantum.html. Accessed March 28 2023"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-011-9271-6"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19367"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2013.00267"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.04.027"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2285"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.4.1905"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041222"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.004"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","unstructured":"BirringS MoriceA SmithJ et al.Responder analyses for patient\u2010reported outcomes in a pooled analysis of two phase III randomized placebo controlled trials of gefapixant a P2X3 receptor antagonist for the treatment of chronic cough. Poster presented at: Annual International Conference of the American Thoracic Society; May 14\u201019 2021; Virtual.","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A2354"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02348-5"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61255-1"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30471-0"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1047"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.924"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00284-2020"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1105"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2094"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T14:23:41Z","timestamp":1692455021000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.12978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/psp4.12978"],"URL":"https:\/\/doi.org\/10.1002\/psp4.12978","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"2023-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}